Immunovia publ AB

Research Immunovia publ AB (IMMNOV) on Bullrun: market cap SEK 102.38M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 102.38M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 684.00K-SEK 145.91M-SEK 83.96Mn/a-0.4SEK 77.46MSEK 857.00KSEK 64.77M
FY2023SEK 1.80M-SEK 309.44M-SEK 147.06Mn/a-7.95SEK 76.79Mn/aSEK 66.99M
FY2022SEK 1.20M-SEK 168.09M-SEK 176.84Mn/a-7.43SEK 106.04Mn/aSEK 243.80M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24SEK 102.38Mn/an/an/a

About Immunovia publ AB

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Immunovia publ AB's market cap?

Immunovia publ AB's market capitalization is SEK 102.38M.

What does Immunovia publ AB do?

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.